Interestingly, the researchers also found that by blocking these THBS1 with antibodies the damage could be reversed. These findings can potentially lead to the development of new therapies for ...

Israeli researchers and their colleagues from the United States developed an antibody-based treatment that empowers the ...

Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash ...

The NbE nanobody (in red) is able to block the receptors (in blue) to which opioids (in white, yellow and red) normally bind, ...

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T ...

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The ...

At least two FDA-approved monoclonal antibodies -- canakinumab and rilonacept -- can block IL-1 signaling. These immunotherapies are approved to treat inflammatory disorders such as juvenile ...

Widespread distribution of nirsevimab to infants with respiratory syncytial virus infection raised concerns about potential ...

Researchers say study offers proof-of-concept that targeting how T cells interact with metabolites in their environment can ...